Market Cap 538.39M
Revenue (ttm) 174.43M
Net Income (ttm) -138.89M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -79.63%
Debt to Equity Ratio 0.00
Volume 839,100
Avg Vol 1,699,602
Day's Range N/A - N/A
Shares Out 384.57M
Stochastic %K 6%
Beta 1.26
Analysts Sell
Price Target $1.55

Company Profile

Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates in two segments, Proteomics and Genomics. Its proteomics and genomics include instruments, consumables, software, and services based upon technologies used in the identification of proteins, as well...

Industry: Medical Devices
Sector: Healthcare
Phone: 650 266 6000
Fax: 650 871 7152
Address:
2 Tower Place, Suite 2000, South San Francisco, United States
Analysis001
Analysis001 Feb. 4 at 6:08 AM
$LAB may be they can execute this over the next 6-12 months. Hope?
0 · Reply
Analysis001
Analysis001 Feb. 3 at 11:44 PM
$LAB : 4. The Endgame: The "Accretive Swap" (Step 2) The Strategy: Once the stock is repriced to ~$1.85+, $LAB.X uses the remaining cash + the now-more-valuable stock to acquire a private unicorn (e.g., Vizgen/Ultivue). The Magic Math: • Share Count: Stays roughly flat (Retire ~80M shares in Tender Issue ~100M shares for Merger). • Revenue: DOUBLES (Adds $100M+ high-growth revenue). • Asset: Swaps "lazy cash" for a high-growth monopoly in Spatial Biology.
0 · Reply
Analysis001
Analysis001 Feb. 3 at 10:59 PM
$LAB 3. The Tax Fix: "Pro-Rata Participation" The Alpha: Casdin (and Viking) will likely SELL into the Tender Offer proportionally. Why this is Bullish: It keeps their ownership % flat (dodging the IRS tax penalty). It lets Casdin book a quick ~40% win on the shares he bought at $1.30. It clears the way for a massive buyback that includes Retail.
0 · Reply
Analysis001
Analysis001 Feb. 3 at 10:59 PM
$LAB 2. The Resolution: The Tender Offer (Step 1) The Move: A $150M Tender Offer priced around $1.85. Why: It forces the stock price up overnight, creating a new floor. The Trap: If the company buys back shares and Casdin holds, his ownership % spikes. This triggers IRS Section 382, wiping out millions in Tax Credits (NOLs).
0 · Reply
Analysis001
Analysis001 Feb. 3 at 10:57 PM
$LAB The "Whale Swap" Blueprint – How BoD Solves the $550M Puzzle Everyone sees the cash ($550M vs $540M Market Cap). Everyone sees the accumulation by hedge funds (Casdin + MAK). But nobody is talking about HOW they unlock it without blowing up the company. Here is the "Game Theory" model for the next 6-12 months. 1. The Price Problem (Why we are stuck at $1.40) • Issue: BoD wants to build a $2B empire, but they can't buy high-growth companies using LAB stock as currency when it’s trading at $1.40. It’s too dilutive. • Constraint: BoD needs the stock at $2.00+ to make any M&A deal math work.
0 · Reply
WHO905
WHO905 Feb. 2 at 3:30 PM
$LAB The sale of SomaLogic completed earlier than estimated. This means current cash on hand is greater than the company's current Market Cap. When will the Street recognize this as a value play? Who is willing to bet that management uses the cash wisely and upcoming M&A is meaningful and good for the top and bottom lines? Hopefully the path to shareholder growth is now upon us.
0 · Reply
Estimize
Estimize Feb. 2 at 12:00 PM
Wall St is expecting -0.05 EPS for $LAB Q4 [Reporting 02/18 AMC] http://www.estimize.com/intro/lab?chart=historical&metric_name=eps&utm_con
0 · Reply
Furderber
Furderber Feb. 2 at 1:04 AM
$LAB Somalogic sold for roughly 300M+75M for performance. LAB has a float of 42M shares, with OS around 384M shares per YahooFinance. That is roughly 9dollars float, or 1 dollar OS.
0 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Jan. 30 at 7:49 PM
$LAB https://www.illumina.com/company/news-center/press-releases/press-release-details.html?newsid=b7bf54f5-b534-47b4-a629-02ade3b10178
0 · Reply
TJ234
TJ234 Jan. 30 at 3:32 PM
$LAB nice $ILMN https://seekingalpha.com/news/4544858-illumina-finishes-somalogic-acquisition?utm_source=webull.com&utm_medium=referral&feed_item_type=news
0 · Reply
Latest News on LAB
Standard BioTools Completes Sale of SomaLogic to Illumina

Jan 30, 2026, 9:09 AM EST - 4 days ago

Standard BioTools Completes Sale of SomaLogic to Illumina


Standard BioTools Reports Third Quarter 2025 Financial Results

Nov 4, 2025, 4:05 PM EST - 3 months ago

Standard BioTools Reports Third Quarter 2025 Financial Results


Standard BioTools Reports Second Quarter 2025 Financial Results

Aug 11, 2025, 4:01 PM EDT - 6 months ago

Standard BioTools Reports Second Quarter 2025 Financial Results


Standard BioTools Reports First Quarter 2025 Financial Results

May 6, 2025, 4:01 PM EDT - 9 months ago

Standard BioTools Reports First Quarter 2025 Financial Results


Standard BioTools Inc. (LAB) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 9:44 PM EST - 1 year ago

Standard BioTools Inc. (LAB) Q4 2024 Earnings Call Transcript


Standard BioTools Inc. (LAB) Q3 2024 Earnings Call Transcript

Oct 30, 2024, 7:10 PM EDT - 1 year ago

Standard BioTools Inc. (LAB) Q3 2024 Earnings Call Transcript


Standard BioTools Inc. (LAB) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 8:34 PM EDT - 1 year ago

Standard BioTools Inc. (LAB) Q2 2024 Earnings Call Transcript


Standard BioTools Announces Senior Leadership Changes

Jul 31, 2024, 4:02 PM EDT - 1 year ago

Standard BioTools Announces Senior Leadership Changes


Standard BioTools Inc. (LAB) Q1 2024 Earnings Call Transcript

May 11, 2024, 12:45 PM EDT - 1 year ago

Standard BioTools Inc. (LAB) Q1 2024 Earnings Call Transcript


Standard BioTools Inc. (LAB) Q4 2023 Earnings Call Transcript

Feb 28, 2024, 8:44 PM EST - 2 years ago

Standard BioTools Inc. (LAB) Q4 2023 Earnings Call Transcript


Standard BioTools Stockholders Approve Merger with SomaLogic

Jan 4, 2024, 10:23 PM EST - 2 years ago

Standard BioTools Stockholders Approve Merger with SomaLogic


Analysis001
Analysis001 Feb. 4 at 6:08 AM
$LAB may be they can execute this over the next 6-12 months. Hope?
0 · Reply
Analysis001
Analysis001 Feb. 3 at 11:44 PM
$LAB : 4. The Endgame: The "Accretive Swap" (Step 2) The Strategy: Once the stock is repriced to ~$1.85+, $LAB.X uses the remaining cash + the now-more-valuable stock to acquire a private unicorn (e.g., Vizgen/Ultivue). The Magic Math: • Share Count: Stays roughly flat (Retire ~80M shares in Tender Issue ~100M shares for Merger). • Revenue: DOUBLES (Adds $100M+ high-growth revenue). • Asset: Swaps "lazy cash" for a high-growth monopoly in Spatial Biology.
0 · Reply
Analysis001
Analysis001 Feb. 3 at 10:59 PM
$LAB 3. The Tax Fix: "Pro-Rata Participation" The Alpha: Casdin (and Viking) will likely SELL into the Tender Offer proportionally. Why this is Bullish: It keeps their ownership % flat (dodging the IRS tax penalty). It lets Casdin book a quick ~40% win on the shares he bought at $1.30. It clears the way for a massive buyback that includes Retail.
0 · Reply
Analysis001
Analysis001 Feb. 3 at 10:59 PM
$LAB 2. The Resolution: The Tender Offer (Step 1) The Move: A $150M Tender Offer priced around $1.85. Why: It forces the stock price up overnight, creating a new floor. The Trap: If the company buys back shares and Casdin holds, his ownership % spikes. This triggers IRS Section 382, wiping out millions in Tax Credits (NOLs).
0 · Reply
Analysis001
Analysis001 Feb. 3 at 10:57 PM
$LAB The "Whale Swap" Blueprint – How BoD Solves the $550M Puzzle Everyone sees the cash ($550M vs $540M Market Cap). Everyone sees the accumulation by hedge funds (Casdin + MAK). But nobody is talking about HOW they unlock it without blowing up the company. Here is the "Game Theory" model for the next 6-12 months. 1. The Price Problem (Why we are stuck at $1.40) • Issue: BoD wants to build a $2B empire, but they can't buy high-growth companies using LAB stock as currency when it’s trading at $1.40. It’s too dilutive. • Constraint: BoD needs the stock at $2.00+ to make any M&A deal math work.
0 · Reply
WHO905
WHO905 Feb. 2 at 3:30 PM
$LAB The sale of SomaLogic completed earlier than estimated. This means current cash on hand is greater than the company's current Market Cap. When will the Street recognize this as a value play? Who is willing to bet that management uses the cash wisely and upcoming M&A is meaningful and good for the top and bottom lines? Hopefully the path to shareholder growth is now upon us.
0 · Reply
Estimize
Estimize Feb. 2 at 12:00 PM
Wall St is expecting -0.05 EPS for $LAB Q4 [Reporting 02/18 AMC] http://www.estimize.com/intro/lab?chart=historical&metric_name=eps&utm_con
0 · Reply
Furderber
Furderber Feb. 2 at 1:04 AM
$LAB Somalogic sold for roughly 300M+75M for performance. LAB has a float of 42M shares, with OS around 384M shares per YahooFinance. That is roughly 9dollars float, or 1 dollar OS.
0 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Jan. 30 at 7:49 PM
$LAB https://www.illumina.com/company/news-center/press-releases/press-release-details.html?newsid=b7bf54f5-b534-47b4-a629-02ade3b10178
0 · Reply
TJ234
TJ234 Jan. 30 at 3:32 PM
$LAB nice $ILMN https://seekingalpha.com/news/4544858-illumina-finishes-somalogic-acquisition?utm_source=webull.com&utm_medium=referral&feed_item_type=news
0 · Reply
TJ234
TJ234 Jan. 27 at 1:38 AM
$LAB when will the deal get sealed for the Somascan part with $ILMN ? Around the corner?
0 · Reply
Furderber
Furderber Jan. 26 at 9:14 PM
$LAB MM kept this tightly ranged bound today. Wonder why?
0 · Reply
DonWestTrading
DonWestTrading Jan. 24 at 1:30 AM
$LAB still not investable. They say you eat with your eyes and this is not delicious. Many say it’s like eating $POOP #poop #elonmusk
0 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Jan. 21 at 10:42 PM
$LAB 75% institutional ownership !!!!!!!!!!!
1 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Jan. 21 at 10:40 PM
$LAB “As we look to 2026, the sale of SomaLogic to Illumina remains on track to close in the first half of the year. At close, we expect to have approximately $550 million in cash and a base business on its way to positive adjusted EBITDA — a combination that creates real strategic flexibility. With an experienced team, a simplified footprint and substantial cash, we are well positioned to pursue disciplined M&A as we work to build a diversified leader in life sciences."
0 · Reply
DonWestTrading
DonWestTrading Jan. 15 at 5:24 AM
$LAB not impressed
1 · Reply
DonWestTrading
DonWestTrading Jan. 13 at 4:29 PM
$LAB standard TOOLS is right. I would not use in my lab.
2 · Reply
WHO905
WHO905 Jan. 13 at 4:25 PM
$LAB $PACB Really tired of watching the algorithms control the pricing on these stocks. It will be really nice to each trade on its own merit with true institutional interest. Market Cap on LAB would be at least $1.5B!
2 · Reply
Jdfulgham1990
Jdfulgham1990 Jan. 13 at 3:44 PM
$LAB volume starting to increase up 5% today and up almost 25% since last week. Low float with heavy support level around $1.50 and short interest currently around 5%. Could move up quickly once volume starts increasing 💪 Also watching $BYND and $PLUG
0 · Reply
Jdfulgham1990
Jdfulgham1990 Jan. 13 at 2:36 PM
Watching both $LAB and $BYND for the next leg up🧨🚀 both have been consolidating nicely building support!!
0 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Jan. 8 at 2:04 PM
0 · Reply
beckphan08
beckphan08 Jan. 8 at 1:32 PM
$LAB 2026 is going to be the year!
0 · Reply